Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

Summary

This is an open-label, switch maintenance study of MRx0518 and Avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) whose disease did not progress after 4 to 6 cycles of first-line platinum-containing chemotherapy and who have residual measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Up to 30 patients will be enrolled. Patients enrolled in this study will be treated with IV Avelumab every 2 weeks and MRx0518 daily during the treatment period. Patients will receive the study treatment until disease progression (PD), patient withdrawal, or unacceptable toxicity.

Timeline

Start

2022-03-01

Primary completion

2023-04

Completion

2023-04

Outcome

Outcome not reported

Stopped: “Sponsor unable to proceed”

Drugs

Indications